NCT02177292Active, not recruiting
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to find out the effects (good and bad) of using newer technologies that allow very precise delivery of radiation. These newer technologies are Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 18 Jun 2014
- Start date
- 23 Jun 2010
- Primary completion date
- 2 Mar 2026
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Prostate cancer
- NCT number
- NCT02177292
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 23 Jun 2010 to the primary completion date, 2 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radical surgery for carcinoma of the prostate
- History of prior chemotherapy
- History of prior pelvic radiation therapy
Age
- Children (age \< 18).
Other
- Clinical or pathological evidence of distant metastases (M1).
Who the study is looking for
- Histologically confirmed, adenocarcinoma of the prostate
- T1-2N0M0 with risk of pelvic lymph nodes involvement \>25% by Roach formula \[(2/3xPSA) + (Gleason Score - 6)x10\], or any T3-4N0M0
- Karnofsky Performance Scale \> 70.
- Prostate tumor biopsy grading by Gleason score classification is mandatory prior to registration.
- No prior pelvic or prostate radiation or chemotherapy for any reason; induction hormonal therapy prior to registration is acceptable.
- Patients must sign a study-specific consent form prior to registration.
- No evidence of distant metastases (Bone scanning)
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Froedtert & the Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.